<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252612</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-19708</org_study_id>
    <nct_id>NCT04252612</nct_id>
  </id_info>
  <brief_title>Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study</brief_title>
  <official_title>Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will treat resectable cutaneous squamous cell carcinoma patients with pramlintide
      for two weeks prior to surgical resection of their tumor. Pre-treatment and surgical
      resection specimens will then be analyzed for biological alterations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Compliance</measure>
    <time_frame>at 14 days from on study date</time_frame>
    <description>Patients who complete at least 75% of the injections and have not missed 2 consecutive days of treatment will be considered compliant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>at 44 days from on study date</time_frame>
    <description>Number of adverse events prior to surgery, during surgery and for 30 days after surgery that may be related to pramlintide injection.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Cutaneous Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Pramlintide 60 mcg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will self inject Pramlintide 60 mcg twice daily for two weeks prior to surgical resection of tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Pramlintide 60 mcg three times daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will self inject Parmlintide 60 mcg three times daily for two weeks prior to surgical resection of tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Pramlintide 120 mcg three times daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will self inject Parmlintide 120 mcg three times daily for two weeks prior to surgical resection of tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramlintide</intervention_name>
    <description>SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.</description>
    <arm_group_label>Cohort 1: Pramlintide 60 mcg twice daily</arm_group_label>
    <arm_group_label>Cohort 2: Pramlintide 60 mcg three times daily</arm_group_label>
    <arm_group_label>Cohort 3: Pramlintide 120 mcg three times daily</arm_group_label>
    <other_name>Symlin</other_name>
    <other_name>SymlinPen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven cutaneous squamous cell carcinoma. Mixed histologies (basaloid,
             spindle, sarcomatoid, etc.) are allowed if the pathology review favors squamous cell
             carcinoma as the majority component. Cancers of unknown primary sites are allowed if
             the clinical history and the site are highly suggestive of a skin cancer primary

          -  Tumor site must be amenable for surgical resection and accessible for pre-treatment
             biopsy

          -  Tumor site must be measurable by caliper measurements or by Response Evaluation
             Criteria in Solid Tumors (RECIST)1.1 imaging - lesions must be ≥1 cm

          -  Eastern Cooperative Oncology Group (ECOG) ≤2 and be medically able to undergo surgical
             resection

          -  Laboratory Requirements: Hemoglobin ≥ 8 g/dl, Platelet count ≥ 50,000/dl, Serum
             Creatinine ≤ 1.5 mg/dL OR Glomular Filtration Rate (GFR) ≥ 40, Serum aspartate
             aminotransferase (AST) and alanine transaminase (ALT) &lt; 2.5x ULN; Total Bilirubin &lt;
             1.5x ULN (for patients with documented history of Gilbert's syndrome, total bilirubin
             level should be &lt; 3.0 X ULN)

          -  Ability to understand and willingness to sign a written informed consent document

          -  Patients with child bearing potential must be willing to use barrier protection to
             prevent pregnancy while on study therapy and up to 30 days after the last dose of
             pramlintide

          -  Female subject of childbearing potential should have a negative urine or serum
             pregnancy within 72 hours prior to receiving the first dose of study medication. If
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required.

          -  Patients must be willing to comply with the protocol for the duration of the treatment
             including daily sub-cutaneous (SQ) injections, biopsies, scheduled visits and
             examinations, radiologic studies, and surgical resection

        Exclusion Criteria:

          -  Type I diabetes: Type II diabetics (DM2) on insulin are allowed, however, for those
             DM2 patients that are on short acting insulin, the insulin dose should be reduced 50%
             and need to have regular glucose monitoring (see section 6.2.1). Type II diabetics not
             on insulin will not be eligible.

          -  Patients with known gastroparesis

          -  Patients with known allergic reactions to pramlintide or its ingredients

          -  Pregnant women and/or nursing patients will be excluded from this study because of
             unknown risks to fetus or nursing infants

          -  Any serious or uncontrolled medical disorder that could interfere with the current
             study as deemed by the investigating physician

          -  Participation in any other clinical study using an investigational agent within 21
             days of starting treatment on this protocol

          -  No prior chemotherapy, radiation, or other tumor directed therapy within 21 days prior
             of starting treatment on this protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikhil Khushalani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neha Pathak</last_name>
      <phone>813-745-5170</phone>
      <email>Neha.Pathak@Moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Nikhil Khushalani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Brohl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zeynep Eroglu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elsa Flores, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Markowitz, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amod Sarnaik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vernon Sondak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmad Tarhini, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Tsai, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Zager, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramlintide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

